Gene Therapy for ACM Due to a PKP2 Pathogenic Variant

Selected Inclusion Criteria:

• Adults with a clinical diagnosis of ACM meeting the 2010 revised Task Force Criteria (TFC)

• Genetic testing documenting a pathogenic or likely pathogenic variant in PKP2

• Frequent premature ventricular complexes (PVCs)

• Implantable cardioverter-defibrillator (ICD) implantation ≥ 12 weeks prior to thepre-screening MRI

• Left ventricular ejection fraction ≥ 40%

Selected Exclusion Criteria:

• Evidence of variant(s) in addition to PKP2 that meets the standard criteria to beconsidered pathogenic or likely pathogenic for ACM

• Other cardiac abnormalities as specified in the protocol

• New York Heart Association Functional Class IV at the time of consent

• History of prior gene transfer therapy